Login to Your Account



VCs 'BET' $19M on Oncoethix's Hematological Cancer Candidate

By Cormac Sheridan
Staff Writer

Tuesday, July 9, 2013
Oncoethix SA raised CHF18 million (US$18.7 million) in a Series B round to move its bromodomain and extra-terminal (BET) inhibitor OTX015 into Phase II proof-of-concept studies in hematological malignancies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription